Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label fremanezumab in pediatric episodic and chronic migraine
2024-512837-34-00Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of fremanezumab in episodic migraine and chronic migraine, sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Safety: Occurrence of adverse events including local injection site reactions/pain, Safety: Changes from baseline in clinical laboratory test results and growth parameters and 4 more. Started Oct 2024; status: completed.
02
Drugs
fremanezumab
03
Conditions
episodic migrainechronic migraine
Beyond the preview
Go deeper on 2024-512837-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512837-34-00.